Rapamycin (Sirolimus) Side Effects: Severity Distribution by Patient Phenotype

What Is the Overall Adverse Event Profile of Sirolimus?

Sirolimus inhibits mTORC1, a serine-threonine kinase that regulates cell growth, protein synthesis, and immune activation. Because mTORC1 signaling touches virtually every tissue, adverse events are broad and class-mediated rather than target-organ specific. The FDA-approved prescribing information lists more than 30 adverse reactions occurring in at least 3% of transplant patients, with hyperlipidemia (45 to 57%), thrombocytopenia (14 to 30%), and anemia (23 to 33%) topping the list across the registration trials [1].

Grading Framework Used in This Article

This article uses the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0) grading scale throughout:

• Grade 1 / mild, asymptomatic or mild symptoms, no intervention required
• Grade 2 / moderate, minimal, local, or non-invasive intervention indicated
• Grade 3 / severe, medically significant but not immediately life-threatening, hospitalization indicated
• Grade 4 / life-threatening, urgent intervention required
• Grade 5 / death

Source Data

Evidence in this article draws on: the Rapamune FDA label (NDA 021083), the FAERS public dashboard (through Q1 2025), the key phase-3 U.S. And global transplant trials (N=719 and N=228 respectively), the MILES trial of sirolimus in LAM, and post-market pharmacovigilance literature [1][2][3].

Metabolic Adverse Events: Hyperlipidemia, Hyperglycemia, and Weight Changes

Metabolic toxicity is the most common reason clinicians adjust or discontinue sirolimus outside the transplant setting.

Hyperlipidemia

MTORC1 inhibition reduces lipoprotein lipase activity and increases hepatic lipogenesis. In the phase-3 U.S. Transplant trial (N=719), hypercholesterolemia occurred in 46% of sirolimus 2 mg/day recipients vs. 23% in the azathioprine arm, and hypertriglyceridemia occurred in 57% vs. 24% [1]. Most cases are grade 1 to 2, responding to statin therapy plus dietary modification. Grade 3 hypertriglyceridemia (triglycerides greater than 500 mg/dL) occurs in roughly 5 to 8% of transplant patients and requires fibrate therapy or dose reduction [4].

Patients with pre-existing familial hypercholesterolemia or metabolic syndrome carry roughly double the risk of reaching grade 3 lipid thresholds compared with normolipidemic recipients, based on a 2019 single-center pharmacovigilance cohort (N=312) [4].

Hyperglycemia and New-Onset Diabetes After Transplant

MTORC1 suppression impairs beta-cell proliferation and insulin signaling. New-onset diabetes after transplant (NODAT) occurs in 9 to 16% of sirolimus-treated renal recipients vs. 6 to 10% with calcineurin inhibitors alone [5]. The risk is roughly tripled in patients with pre-transplant impaired fasting glucose (IFG), a phenotype that should trigger prophylactic metformin consideration and monthly glucose monitoring for the first six months [5].

Low-Carbohydrate and Off-Label Longevity Use

In off-label longevity cohorts using 1 to 6 mg/week intermittent dosing, the PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity, ongoing Phase 2, NCT04488601) reported grade 1 to 2 mouth sores in 27% and grade 1 fasting glucose elevation in 18% at 24 weeks, with no grade 3/4 metabolic events at the 5 mg/week dose arm [6]. Patients with baseline HbA1c above 5.7% showed a 2.3-fold higher rate of fasting glucose elevation.

Hematologic Adverse Events: Thrombocytopenia, Anemia, and Leukopenia

Sirolimus suppresses megakaryocyte differentiation and erythropoiesis by blocking mTORC1 in bone marrow progenitors [7].

Thrombocytopenia

Thrombocytopenia (platelet count below 100,000/mm³) occurs in 14 to 30% of transplant patients, is usually grade 1 to 2, and typically resolves with dose reduction. Grade 3 thrombocytopenia (platelets below 50,000/mm³) was reported in 4.5% of patients in the global trial (N=228) [1]. Patients receiving concurrent mycophenolate mofetil (MMF) show additive marrow suppression, pushing thrombocytopenia incidence above 35% in some center reports.

Anemia and TMA Risk

Grade 1 to 2 anemia occurs in 23 to 33% of sirolimus recipients. A clinically distinct phenotype is thrombotic microangiopathy (TMA), a grade-4 event characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal injury. TMA occurs in roughly 1 to 3% of patients on sirolimus plus a calcineurin inhibitor (CNI), with tacrolimus conferring higher risk than cyclosporine [8]. Discontinuation of sirolimus is mandatory when TMA is confirmed.

Pulmonary Adverse Events: Pneumonitis and Pleural Effusion

Sirolimus-associated pneumonitis (SAP) is the most feared non-infectious pulmonary complication and the one with the clearest dose-trough relationship.

Incidence and Severity

SAP incidence across post-market series ranges from 2.5% to 11% in transplant populations, with a median onset of 7 to 12 months after initiation [9]. The FAERS disproportionality analysis shows a reporting odds ratio of 8.4 for sirolimus vs. All other drugs, making it one of the strongest pneumonitis signals in the entire drug database. Grade 3 to 4 pneumonitis (requiring oxygen supplementation or mechanical ventilation) accounts for roughly 30% of all SAP cases in published series [9].

Phenotype Risk Factors for SAP

Three patient characteristics independently associate with SAP risk:

1. Trough sirolimus concentration above 15 ng/mL (odds ratio approximately 3.1, 95% CI 1.7 to 5.6) [9]
2. Pre-existing interstitial lung disease or smoking history (hazard ratio approximately 2.4) [10]
3. Male sex (reported in approximately 70% of SAP cases despite roughly equal sex distribution in transplant populations) [9]

Management

Stopping sirolimus resolves SAP in 60 to 80% of cases within 4 to 8 weeks. Corticosteroids (prednisone 0.5 to 1 mg/kg/day tapered over 6 to 8 weeks) are used for grade 3 to 4 presentations [10]. Rechallenge at a lower dose is reported in small series but carries a recurrence rate of approximately 40%.

Pleural and Pericardial Effusion

Pleural effusion occurs in 3 to 7% of transplant recipients and may be bilateral. It is more common in the setting of lymphedema and lymphangioleiomyomatosis (LAM). In the MILES trial of sirolimus for LAM (N=89), pleural effusion occurred in 22% of sirolimus recipients vs. 5% of placebo [3]. Grade 3 effusions requiring thoracentesis occurred in 6%.

Infectious Adverse Events: Opportunistic Infections and Wound Healing

Opportunistic Infections

MTOR inhibition blunts T-cell proliferation and macrophage activation, increasing susceptibility to opportunistic pathogens. Cytomegalovirus (CMV) viremia occurs in 9 to 25% of sirolimus-treated transplant recipients; Pneumocystis jirovecii pneumonia (PJP) occurs in up to 5% without prophylaxis [1][11]. Standard-of-care now mandates trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis for at least 12 months post-transplant [11].

Patients who are CMV-seronegative receiving a seropositive organ (D+/R-) carry the highest infectious risk and should receive valganciclovir prophylaxis for a minimum of 6 months when on sirolimus-based regimens, per KDIGO 2022 guidelines [11].

Wound Healing Complications

MTORC1 inhibition delays fibroblast proliferation and collagen synthesis. In the combined transplant registration trials, wound dehiscence or lymphocele occurred in 12 to 16% of sirolimus recipients vs. 6% in control arms [1]. The risk is highest in obese recipients (BMI above 30 kg/m²) and those undergoing sirolimus initiation within 30 days of surgery. Most transplant centers now delay sirolimus initiation to 30 to 90 days post-operation and avoid it entirely in the immediate post-surgical window.

Renal Adverse Events: Proteinuria and GFR Decline

Proteinuria

Sirolimus causes podocyte injury and glomerular protein leak independent of CNI co-exposure. In a systematic review of 22 studies (N=1,842), proteinuria above 1 g/day developed in 17 to 30% of patients converted to sirolimus monotherapy from CNI-based regimens [12]. Nephrotic-range proteinuria (above 3.5 g/day) occurred in approximately 5% and predicted allograft failure in long-term follow-up.

eGFR Trajectory

Contrary to early expectations that sirolimus would be "nephroprotective" by avoiding CNI nephrotoxicity, several CNI-withdrawal trials showed worse allograft survival when sirolimus was used as the sole maintenance agent in patients with pre-existing proteinuria. The CONVERT trial (N=830) showed that conversion from CNI to sirolimus in patients with eGFR below 40 mL/min/1.73m² led to higher rates of graft loss at 24 months compared with CNI continuation [13]. Patients with eGFR above 40 mL/min/1.73m² and urine protein below 500 mg/day benefit most from conversion.

Dermatologic and Mucosal Adverse Events

Mouth Ulcers (Aphthous Stomatitis)

Aphthous stomatitis is the single most common adverse event across all sirolimus use cases, occurring in 25 to 44% of transplant patients and 27% of off-label longevity cohort participants [1][6]. It is typically grade 1 to 2, responds to topical triamcinolone 0.1% paste or dexamethasone mouthwash, and rarely requires dose reduction.

Sirolimus Mucosal Toxicity Management Ladder (HealthRX Clinical Framework):

| Grade | Description | First-Line Action | |-------|-------------|-------------------| | 1 | Asymptomatic ulcers, eating unaffected | Topical triamcinolone 0.1% paste TID | | 2 | Painful, modified diet required | Add dexamethasone 0.5 mg/5 mL swish-and-spit; consider dose reduction of 25% | | 3 | Unable to eat or drink adequately | Hold sirolimus; IV fluids if needed; restart at 50% dose after resolution | | 4 | Life-threatening (rare) | Permanent discontinuation |

Acneiform Rash and Folliculitis

Acneiform rash occurs in 20 to 30% of patients and correlates with trough concentration. It responds to topical clindamycin or doxycycline 100 mg/day orally. Severe cases may require sirolimus dose reduction.

Severity Distribution by Patient Phenotype: A Comparative Summary

The table below synthesizes trial and pharmacovigilance data to show how grade 3/4 adverse event rates differ across five key patient phenotypes [1][4][8][9][12][13].

| Phenotype | Dominant Grade 3/4 AE | Estimated Grade 3/4 Rate | Key Modifier | |-----------|----------------------|--------------------------|--------------| | Renal-transplant recipient, standard risk | Thrombocytopenia, infection | 15 to 25% | CNI co-exposure, MMF | | Renal-transplant recipient with diabetes | NODAT complications, wound infection | 25 to 35% | Pre-transplant IFG | | LAM patient (sirolimus monotherapy) | Pleural effusion, pneumonitis | 8 to 15% | Baseline FEV1 | | Off-label longevity user (<6 mg/week) | Mouth ulcers, hyperlipidemia | <5% | Dose, baseline lipids | | Solid-organ recipient with pre-existing ILD | Pneumonitis | 20 to 30% | Trough above 15 ng/mL |

The off-label longevity phenotype shows the lowest grade 3/4 burden, primarily because doses are roughly 10-fold lower than transplant maintenance doses and troughs typically remain below 5 ng/mL. The diabetic transplant recipient carries the highest composite burden.

Drug Interactions That Amplify Adverse Event Severity

Several drug classes shift sirolimus troughs into ranges associated with grade 3/4 toxicity by inhibiting or inducing CYP3A4 and P-glycoprotein [1]:

• Strong CYP3A4 inhibitors (ketoconazole, voriconazole, diltiazem): may raise sirolimus AUC by 3- to 11-fold. Co-administration requires 90% dose reduction and intensive trough monitoring.
• Strong CYP3A4 inducers (rifampin, carbamazepine): may reduce sirolimus AUC by up to 82%. Avoid co-administration when possible.
• Grapefruit juice: inhibits intestinal CYP3A4 and can raise troughs unpredictably by 20 to 50%; patients should avoid it entirely.

The FDA label states: "The co-administration of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) is not recommended." [1]

Monitoring Protocol to Minimize Preventable Grade 3/4 Events

Based on the FDA label, KDIGO 2022 transplant guidelines, and the LAM Foundation clinical guidance, the following minimum monitoring schedule applies to sirolimus-treated patients [1][11][14]:

First 3 months:

• CBC with differential every 2 weeks
• Comprehensive metabolic panel (fasting lipids, glucose) every 2 weeks
• Sirolimus trough level every 2 weeks until two consecutive levels are in range

Months 3 to 12:

• CBC and metabolic panel monthly
• Sirolimus trough monthly
• Urinalysis with spot urine protein/creatinine ratio every 3 months
• Chest radiograph if any respiratory symptom

Beyond 12 months:

• CBC and metabolic panel every 3 months
• Sirolimus trough every 3 months or after any dose change or new interacting drug

Dr. Jill Shemesh, a clinical pharmacologist writing in the American Journal of Transplantation, noted: "Trough-guided dosing is not optional in sirolimus management. The margin between efficacy and grade 3 toxicity is narrow enough that even a single missed interaction check can shift a patient from therapeutic to toxic within days." [14]

Special Populations With Heightened Adverse Event Risk

Pediatric Patients

Children metabolize sirolimus faster than adults (higher weight-normalized clearance). Initial dosing is typically 3 mg/m² loading dose, then 1 mg/m² maintenance, with trough targets of 10 to 15 ng/mL in the early post-transplant period. Growth impairment (reduced IGF-1 signaling via mTORC1) and lipid abnormalities are the dominant pediatric concerns [1].

Patients Over 65

Older adults show reduced sirolimus clearance due to lower CYP3A4 activity, and grade 1 to 2 infections progress to grade 3 to 4 more often because of baseline immune senescence. In FAERS data through Q1 2025, patients over 65 account for 38% of serious adverse event reports for sirolimus despite representing a smaller fraction of the overall treated population.

Patients With Hepatic Impairment

Severe hepatic impairment (Child-Pugh Class C) reduces sirolimus clearance by approximately 61%, necessitating a dose reduction of roughly 33 to 50% and more frequent trough monitoring [1]. Mild-to-moderate impairment (Child-Pugh A/B) requires trough monitoring but not automatic dose reduction.